IFRX
InflaRx N.V. NASDAQ Listed Nov 7, 2017$1.81
-0.55%
vs $1.82
Mkt Cap $121.8M
52w Low $0.79
52.3% of range
52w High $2.74
50d MA $1.96
200d MA $1.34
P/E (TTM)
-2.7x
EV/EBITDA
—
P/B
2.9x
Debt/Equity
0.0x
ROE
—
P/FCF
-3.6x
RSI (14)
25.20
ATR (14)
$0.15
Beta
1.51
50d MA
$1.96
200d MA
$1.34
Avg Volume
1.9M
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Winzerlaer Str. 2 · Jena, 2M 07745 · DE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 2.50 | -4.4% | +6.0% | -2.6% | -3.1% | -2.8% | +3.7% | — |
| Mar 19, 2026 | AMC | -0.18 | -0.17 | +5.6% | 0.91 | -2.2% | +3.3% | +3.0% | +5.4% | -7.8% | -1.1% | — |
| Nov 10, 2025 | AMC | -0.16 | -0.16 | +0.0% | 1.58 | +5.1% | +4.4% | -11.5% | -13.0% | +6.3% | -8.1% | — |
| Aug 7, 2025 | AMC | -0.24 | -0.24 | +0.0% | 0.82 | +0.9% | -1.8% | +2.8% | +1.2% | -2.0% | +1.4% | — |
| May 7, 2025 | AMC | -0.18 | -0.14 | +22.2% | 1.49 | +2.0% | +6.0% | +1.9% | +3.7% | +7.2% | +2.8% | — |
| Mar 20, 2025 | AMC | -0.27 | -0.09 | +66.7% | 1.26 | +0.0% | +1.6% | +10.2% | -5.7% | -6.8% | +0.8% | — |
| Nov 8, 2024 | AMC | -0.27 | -0.33 | -22.2% | 1.56 | -1.9% | -1.9% | -1.3% | +13.2% | +18.7% | -3.9% | — |
| Aug 8, 2024 | AMC | -0.21 | -0.26 | -23.8% | 1.34 | +7.5% | +3.0% | -1.4% | +1.5% | -2.2% | +0.0% | — |
| May 8, 2024 | AMC | -0.24 | -0.19 | +20.8% | 1.20 | +8.3% | +0.0% | -1.7% | +5.9% | +14.4% | -2.1% | — |
| Mar 21, 2024 | AMC | -0.20 | -0.30 | -50.0% | 1.54 | -0.6% | -3.2% | +3.4% | +0.0% | +0.0% | +0.0% | — |
| Nov 1, 2023 | AMC | -0.29 | -0.14 | +51.7% | 1.62 | +0.0% | -13.6% | -1.4% | -0.7% | +8.0% | -4.1% | — |
| Aug 10, 2023 | AMC | -0.36 | -0.15 | +58.3% | 4.00 | +0.0% | -5.5% | -3.4% | -5.5% | -2.0% | +12.1% | — |
| May 11, 2023 | AMC | -0.30 | -0.27 | +10.0% | 4.90 | +0.4% | +4.1% | -5.1% | +1.0% | -2.9% | -8.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13 | Raymond James | Upgrade | Outperform → Strong Buy | $9 | $2.43 | $2.64 | +8.6% | +3.7% | -5.6% | +3.8% | +1.2% | -5.2% |
| Apr 24 | Oppenheimer | Reiterates | Outperform | $5 | $1.56 | $1.61 | +3.2% | -5.1% | +8.8% | +3.7% | +18.6% | +4.5% |
| Apr 21 | Guggenheim | Maintains | Buy → Buy | — | $1.66 | $1.65 | -0.6% | +4.2% | -7.5% | -2.5% | -5.1% | +8.8% |
| Mar 20 | Guggenheim | Maintains | Buy → Buy | — | $0.91 | $0.89 | -2.2% | +3.3% | +3.0% | +5.4% | -7.8% | -1.1% |
| Dec 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.02 | $0.99 | -2.9% | +0.0% | -1.0% | +7.9% | +4.6% | +2.6% |
| Dec 3 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $0.99 | $1.00 | +0.6% | +2.6% | +7.8% | -3.6% | +0.0% | +0.0% |
| Nov 10 | Guggenheim | Maintains | Buy → Buy | — | $1.23 | $1.77 | +43.9% | +28.5% | +4.4% | -11.5% | -13.0% | +6.3% |
| May 29 | Oppenheimer | Maintains | Outperform → Outperform | — | $0.73 | $0.77 | +5.4% | +16.4% | -5.6% | +0.9% | +8.6% | -3.4% |
| Mar 26 | Guggenheim | Maintains | Buy → Buy | — | $1.33 | $1.35 | +1.5% | -6.8% | +0.8% | -8.0% | -11.3% | +2.9% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.26 | $1.26 | +0.0% | +1.6% | +10.2% | -5.7% | -6.8% | +0.8% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.21 | $1.25 | +3.3% | +0.0% | -1.7% | -0.8% | +4.2% | -6.5% |
| Jan 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.52 | $2.53 | +0.4% | +1.2% | -0.4% | -2.8% | +1.2% | -5.2% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.13 | $2.08 | -2.3% | +5.2% | +11.6% | +0.4% | +4.0% | -0.8% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.03 | $2.18 | +7.4% | -3.9% | -10.8% | +10.3% | +6.2% | +1.0% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.56 | $1.53 | -1.9% | -1.9% | -1.3% | +13.2% | +18.7% | -3.9% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.54 | $1.57 | +1.9% | -1.3% | +1.3% | +1.9% | -2.5% | -1.3% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.54 | $1.58 | +2.6% | +8.4% | -3.0% | -1.2% | +4.4% | +4.2% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.58 | $1.64 | +3.8% | +1.9% | +0.0% | -1.9% | -1.3% | +1.9% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.20 | $1.30 | +8.3% | +0.0% | -1.7% | +5.9% | +14.4% | -2.1% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.54 | $1.53 | -0.6% | -3.2% | +3.4% | +0.0% | +0.0% | +0.0% |
| Jan 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.60 | $1.68 | +5.0% | -6.2% | +2.7% | +11.7% | -4.1% | -1.8% |
| Nov 2 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $1.62 | $1.62 | +0.0% | -13.6% | -1.4% | -0.7% | +8.0% | -4.1% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.00 | $4.00 | +0.0% | -0.5% | -2.3% | -0.8% | -2.1% | -6.3% |
| Aug 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.11 | $4.02 | -2.2% | -3.9% | +5.1% | -1.9% | +1.5% | -5.1% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.00 | $4.00 | +0.0% | -5.5% | -3.4% | -5.5% | -2.0% | +12.1% |
| May 12 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $4.90 | $4.92 | +0.4% | +4.1% | -5.1% | +1.0% | -2.9% | -8.0% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.90 | $4.92 | +0.4% | +4.1% | -5.1% | +1.0% | -2.9% | -8.0% |
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.70 | $4.62 | -1.7% | -4.7% | +6.3% | -1.3% | -0.4% | -0.6% |
| Apr 6 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $6.10 | $5.99 | -1.8% | -9.8% | -10.0% | +0.6% | -17.7% | +6.3% |
| Apr 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.77 | $5.01 | +32.9% | +61.8% | -9.8% | -10.0% | +0.6% | -17.7% |
| Apr 5 | Guggenheim | Upgrade | Neutral → Buy | — | $3.77 | $5.01 | +32.9% | +61.8% | -9.8% | -10.0% | +0.6% | -17.7% |
| Apr 5 | LifeSci Capital | Upgrade | Market Perform → Outperform | — | $3.77 | $5.01 | +32.9% | +61.8% | -9.8% | -10.0% | +0.6% | -17.7% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.92 | $3.01 | +3.1% | -3.8% | -6.0% | +0.8% | +0.4% | +4.5% |
| Nov 10 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $2.68 | $2.70 | +0.7% | -4.1% | +4.3% | -8.6% | +4.9% | -1.9% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.91 | $3.08 | +5.8% | +6.9% | -2.3% | +3.3% | -3.2% | -1.6% |
| May 13 | Credit Suisse | Maintains | Underperform → Underperform | — | $1.46 | $1.59 | +8.9% | +0.0% | -4.8% | +6.5% | -2.7% | +4.2% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.46 | $1.59 | +8.9% | +0.0% | -4.8% | +6.5% | -2.7% | +4.2% |
| May 13 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $1.46 | $1.59 | +8.9% | +0.0% | -4.8% | +6.5% | -2.7% | +4.2% |
| May 12 | SVB Leerink | Maintains | Outperform → Outperform | — | $1.37 | $1.36 | -0.7% | +6.6% | +0.0% | -4.8% | +6.5% | -2.7% |
| Mar 25 | SVB Leerink | Maintains | Outperform → Outperform | — | $2.47 | $2.50 | +1.2% | +1.6% | -6.8% | -1.3% | +3.5% | -23.4% |
| Nov 8 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $4.65 | $4.50 | -3.2% | +0.2% | +5.6% | -5.1% | +5.1% | +13.6% |
| Oct 28 | Raymond James | Upgrade | Outperform → Strong Buy | — | $2.86 | $4.24 | +48.3% | +42.0% | +4.4% | +11.8% | +5.3% | -2.2% |
| Aug 6 | Raymond James | Maintains | Outperform → Outperform | — | $2.58 | $2.56 | -0.8% | +1.6% | +0.8% | -3.0% | -3.1% | -0.8% |
| Aug 6 | Credit Suisse | Maintains | Underperform → Underperform | — | $2.58 | $2.56 | -0.8% | +1.6% | +0.8% | -3.0% | -3.1% | -0.8% |
| May 13 | Credit Suisse | Maintains | Underperform → Underperform | — | $2.85 | $2.91 | +2.1% | -4.6% | +2.6% | -1.4% | -0.7% | +4.0% |
| May 13 | Raymond James | Maintains | Outperform → Outperform | — | $2.85 | $2.91 | +2.1% | -4.6% | +2.6% | -1.4% | -0.7% | +4.0% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.89 | $3.96 | +1.8% | +4.4% | -10.8% | +4.7% | +2.9% | +3.6% |
| Mar 11 | Guggenheim | Upgrade | Neutral → Buy | — | $4.45 | $4.81 | +8.1% | +6.3% | +1.3% | +0.4% | -2.5% | +0.4% |
| Jan 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.74 | $5.96 | +3.8% | +8.7% | +1.1% | -4.4% | -7.8% | +6.1% |
| Nov 6 | SVB Leerink | Upgrade | Market Perform → Outperform | — | $4.15 | $4.30 | +3.6% | +6.3% | -7.7% | -2.5% | +3.3% | -0.5% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 19
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 2,122,468 | $2M | Added | Dec 2025 |
| 2 | Bank Of America Corp /de/ | 1,975,000 | $2M | Reduced | Mar 2026 |
| 3 | Marshall Wace, Llp | 554,364 | $493K | Added | Mar 2026 |
| 4 | Raymond James Financial Inc | 395,803 | $354K | Added | Mar 2026 |
| 5 | Jane Street Group, Llc | 181,716 | $184K | Added | Dec 2025 |
| 6 | Two Sigma Investments, Lp | 189,075 | $169K | Reduced | Mar 2026 |
| 7 | Adar1 Capital Management, Llc | 158,271 | $142K | New | Mar 2026 |
| 8 | Susquehanna International Group, Llp | 77,114 | $69K | Added | Mar 2026 |
| 9 | Insigneo Advisory Services, Llc | 60,250 | $54K | — | Mar 2026 |
| 10 | Concurrent Investment Advisors, Llc | 52,951 | $53K | Added | Dec 2025 |
| 11 | Ubs Group Ag | 29,800 | $27K | Reduced | Mar 2026 |
| 12 | Citadel Advisors Llc | 26,037 | $23K | Reduced | Mar 2026 |
| 13 | Hrt Financial Lp | 15,997 | $14K | Reduced | Mar 2026 |
| 14 | Pacifica Partners Inc. | 14,210 | $13K | — | Mar 2026 |
| 15 | Bnp Paribas Financial Markets | 10,600 | $9K | Added | Mar 2026 |
| 16 | Axiom Investment Management Llc | 10,000 | $9K | New | Mar 2026 |
| 17 | Citigroup Inc | 1,301 | $1K | — | Dec 2025 |
| 18 | Steward Partners Investment Advisory, Llc | 375 | $335 | Reduced | Mar 2026 |
| 19 | Jpmorgan Chase & Co | 335 | $279 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$121.8M
Enterprise Value
$75.4M
P/E (TTM)
-2.74x
Forward P/E
—
PEG Ratio
0.09x
P/B
2.93x
P/S
4323.00x
P/FCF
-3.58x
EV/EBITDA
—
Shares Out
67.3M
Financials (TTM)
Revenue
$28K
Net Income
-$43.8M
EBITDA
-$48.5M
Free Cash Flow
-$34.0M
Op Cash Flow
-$33.9M
EPS Basic
$-0.66
EPS Diluted
$-0.66
EPS Forward
$-0.62
Gross Margin
-26108.5%
Op Margin
-173594.0%
Net Margin
-155584.2%
Balance Sheet
Total Assets
$55.2M
Total Liab.
$13.7M
Total Equity
$41.5M
Cash
$46.4M
LT Debt
$0
Book Value/Sh
$0.62
Debt/Equity
0.02x
Current Ratio
4.13
Quick Ratio
4.13
Returns & Growth
ROE
—
ROA
—
ROIC
-115.1%
Rev Growth YoY
-83.0%
EPS Growth YoY
+15.4%
Price Returns
2W
+0.8%
1M
+15.9%
3M
+160.9%
6M
+90.5%
12M
+199.1%
Technicals
52W High
$2.74
52W Low
$0.79
50d MA
$1.96
200d MA
$1.34
RSI (14)
25.20
ATR (14)
$0.15
Beta
1.51
Avg Volume
1.9M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$2.00
High
$2.00
Low
$2.00
Median
$2.00
Data updated apr 25, 2026 3:04pm
· Source: financialmodelingprep.com